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Introduction

43
Porcine circovirus (PCV) is a small, non-enveloped, single-stranded DNA virus 44 which belongs to the family Ciroviridae (1). PCV type 1 (PCV1) was originally 45 identified as a cell culture contaminant of the porcine kidney cell line PK-15 in the 46 1970's, and was later found to be non-pathogenic in pigs (2, 3). In 1997, a pathogenic 47 variant designated as PCV type 2 (PCV2) was identified in wasting piglets shortly after 48 weaning (2, 4-9). As more cases were identified worldwide, PCV2 was determined to be 49 the primary causative agent of porcine circovirus-associated disease (PCVAD), which 50 includes a broad spectrum of clinical symptoms such as wasting, reproductive failure, 51 respiratory signs and enteritis, and PCV2 may also have a role in the porcine dermatitis 52 and nephropathy syndrome (10) . 53 PCV2 is one of the most economically devastating viral pathogens to affect the 54 global pig industry to date, and vaccination has been an effective strategy to reduce the 55 economic losses associated with PCV2 infection (11). Currently, all commercially 56 available inactivated or subunit vaccines target theconsist of a single PCV2a subtype 57 capsid antigen (11) (12) (13) (14) . However, since 2005, a new subtype, PCV2b, has taken over as 58 the most prevalent PCV2 strain associated with PCVAD cases in the U.S. and other 59 countries (15) (16) (17) . In addition, newly emerging PCV2d strains (previously referred to as 60 "mutant PCV2b"), have been identified in an increasing number of cases in vaccinated 61 herds worldwide, leading to the speculation by some that the emerging PCV2d strains are 62 able to overcome vaccine protection (18) (19) (20) . A recent study showed that animals 63 vaccinated with recombinant PCV2a capsid protein had lower viral loads and generated 64 higher neutralizing antibodies against a PCV2d-1 strain than vaccination with either a1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 PCV2b or homologous PCV2d-1 recombinant capsid protein, suggesting that PCV2 66 capsid immunogenicity varies (21). However this could not fully explain how PCV2d 67 infections are emerging in PCV2a vaccinated herds. 68
Until recently, only three PCV2 subtypes were recognized, including PCV2a, 69
PCV2b, and PCV2c, the last of which was identified in Denmark during the 2000's, is 70 recognized but not very prevalent (22, 23) . While the majority of the PCVAD cases in 71 the United States are now associated with PCV2b, the emerging PCV2d subtype has been 72 slowly increasing in the U.S since its initial discovery in 2012 and is now more prevalent 73 than PCV2a (24). Although the exact reason for the emergence of PCV2d remains 74 unclear, it can be commonly found in vaccinated herds, leading to the speculation of 75 either reduced protection against this emerging PCV2d or vaccination failure of 76 individual animals (18) . While the introduction of PCV2a based vaccine strategies has 77 resulted in a drastic decline in PCV2 prevalence (25), the increased genetic diversity of 78 PCV2 strains is concerning, and is suggestive of selective pressure promoting genetic 79 diversity. In fact, a recent report has demonstrated the increasing genetic diversity 80 amongst the PCV2d subtype, as the majority of isolates identified from 1999-2011 can be 81 classified under the subclade "PCV2d-1," and the majority of isolates identified recently, 82 from 2006-2014, diverge from the PCV2d-1 subclade and are now designated "PCV2d-83 2" (24). In addition, in vitro evidence suggests distinct antigenic differences among 84 PCV2 subtypes, which may help explain the emergence of new strains (26, 27) . 85 Therefore, in order to address the concern of emerging PCV2d as well as the predominant 86
PCV2b now circulating in global swine herds, as well as the possibility for the generation 87 of increasingly divergent PCV2 strains that cannot be controlled by vaccination with a1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 PCV2a antigen alone, future vaccine strategies should focus on broadening the protection 89 of a single vaccine by targeting emerging strains such as PCV2d and the predominant 90 PCV2b subtype. 91 DNA shuffling has been shown to be a powerful tool to introduce genetic 92 diversity into the virus of interest (28, 29) . In fact, recently our group has successfully 93 shuffled the structural genes of porcine reproductive and respiratory syndrome virus 94 (PRRSV) and developed chimeric virus vaccine candidates with broadly protective 95 properties against heterologous PRRSV strains (30-33). Therefore, in the present study 96 we aimed to molecularly breed by DNA shuffling the capsid genes of 5 genetically 97 diverse PCV2 subtypes including PCV2a, PCV2b, PCV2c, PCV2d and a capsid sequence 98 representing a recently identified divergent PCV2a virus previously referred to as 99 "PCV2e." "PCV2e" The "PCV2e" genotype was (originally identified by phylogenetic 100 analysis of the capsid sequence (34), but was later determined be included in theor 101 divergent PCV2a genotype based on full sequence phylogenetic analysis (35)). While the 102 "PCV2e" strains identified are not divergent enough from PCV2a strains to be referred to 103 as their own genotype, this strain was included in this study to increase genetic diversity 104 of the PCV2 capsids utilized for DNA shuffling, and will be referred to as "divergent 105 PCV2a" in this paper to separate it from the classic PCV2a strain used in this study. In in 106 order to create a chimeric virus that can induce broad cross-protection against different 107 PCV2 subtypes especially the emerging PCV2d and the currently predominant circulating 108
PCV2b. 109
We were able to successfully generate four viable chimeric viruses with shuffled 110 capsid gene sequences in the backbone of PCV2a. An in vivo pilot study was first1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 conducted in pigs to assess the infectivity and cross-neutralizing activities of these 4 112 chimeric viruses. The chimeric virus (3cl14) exhibiting the highest level of cross-113 neutralizing activity against different PCV2 subtypes were subsequently selected for a 114 challenge and efficacy study in pigs against the currently predominant circulating PCV2b 115 strain as well as the emerging PCV2d strain. We demonstrated that the capsid-shuffled 116 chimeric virus 3cl14 induces protective immunity in conventional pigs against challenges 117 with both PCV2b and PCV2d. 118
119
Materials and Methods
120
Cells: A subclone of the PK-15 cell line that is free of PCV1 contamination was 121 produced previously by end-point dilution of PK-15 cells (ATCC CCL-33) (36). This 122 subclone PK-15 cell line was cultured in Minimal Essential Medium (MEM) 123 supplemented with 10% Fetal Bovine Serum (FBS) and antibiotics and was used in the 124 serum virus neutralization assay and to propagate all virus stocks for this study. 125 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 "divergent PCV2aPCV2e" capsid genes were synthesized by GenScript (PIscataway, 134
NJ). 135
Traditional DNA shuffling was used to shuffle the 5 different PCV2 capsid genes 136 essentially as previously described for PRRSV (31), with slight modifications. Briefly, 137 the capsid gene DNAs from each of the five PCV2 strains were mixed in equimolar 138 amounts with a total of 5 µg DNA and diluted in 50 µl of 50 mM Tris-HCl (pH 7.4) and 139 10 mM MgCl2. The mixture was incubated at 15°C for 3 min with 0.15 U of DNase I 140 (Sigma). DNA fragments ranging from 50 to 150 bp in size were purified from 2% 141 agarose gels, and subsequently added to the Pfu PCR mixture consisting of 1X Pfu 142 buffer, 0.2 mM each deoxynucleoside triphosphate (dNTP), and 0.06 U Pfu polymerase. 143 A PCR program without using primers (95°C for 4 min; 40 cycles of 95°C for 30s, 60°C 144 for 30s, 57°C for 30s, 54°C for 30s, 51°C for 30s, 48°C for 30s, 45°C for 30s, 42°C for 145 30s, and 72°C for 2 min; and finally, 72°C for 7 min) was performed to reassemble the 146 digested DNA fragments. Subsequently, specific primers flanking the shuffled PCV2 147 capsid region, UniRep-F and 2aORF2-R (Table S1) , were used to amplify the shuffled 148 PCV2 capsid using Pfu Ultra II Hotstart PCR Master Mix (Agilent Technologies) per the 149 manufacturer's instructions (95°C for 4 min, 10 cycles of 95°C for 30s, 50°C for 30s, 150 72°C for 30s, 25 cycles of 95°C for 30s, 54°C for 30s, 72°C for 30s, and finally 72°C for 151
min). 152 153
Construction of infectious DNA clones of chimeric PCV2a and PCV1 viruses with 154
shuffled PCV2 capsid genes: The shuffled capsid gene product libraries were cloned 155 into the blunt end cloning vector, pCR-Blunt II, using the Zero Blunt  ® TOPO  ® PCR1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Cloning kit (Life Technologies, Carlsbad), per manufacturer's instructions. Selected 157 clones were sequenced and analyzed for DNA shuffling efficiency, and well-shuffled 158 capsid genes containing regions from all 5 PCV2 subtypes were amplified and 159 subsequently cloned into the infectious DNA clone backbone of the PCV2a strain 40895 160 by fusion PCR, essentially as previously described (38). Briefly, the shuffled PCV2 161 capsids were amplified using primers UniRep-F and 2aORF2-R ( Table S1 ). The PCV2a 162 infectious DNA clone backbone sequence was amplified in two fragments that flank the 163 PCV2 capsid region using primers SacII-uni-F and UniRep-R, and primers 2aORF2F and 164
SacII-uni-R, for PCV2a fragments 1 and 2, respectively ( Table S1 ). All three PCR 165 reactions were performed using ACCUZYME MIX TM (Bioline) at 95°C 10 min, 35 166 cycles of 95°C for 30s, 54°C for 30s, and 68°C for 1.5 min. The first fusion PCR was 167 performed with the PCV2 fragment 1 and the shuffled PCV2 capsid sequence using the 168 external primers SacII-uni-F and 2aORF2-R. Subsequently, a second fusion PCR reaction 169 was performed with the product of the first fusion PCR reaction and the PCV2a fragment 170 2, using the external primers SacII-uni-F and SacII-uni-R ( Table S1 ). All fusion PCR 171 reactions were performed using ACCUZYME MIX TM at 95°C 10 min, 35 cycles of 95°C 172 for 30s, 60°C for 30s, and 68°C for 4 min. The full-length chimeric PCV2a containing 173 each individual shuffled PCV2 capsid was amplified, and cloned into the pCR-Blunt II 174 TOPO plasmid using the Zero Blunt ® cloning kit to produce infectious DNA clones of 175 chimeric PCV2a with shuffled capsid genes. 176
The shuffled PCV2 capsid 3cl14 was cloned into the infectious DNA clone 177 backbone of the non-pathogenic PCV1 to create the vaccine candidate PCV1-3cl14 by a 178 similar fusion PCR protocol. Briefly, the shuffled PCV2 capsid 3cl14 was amplified using primers PCV1-BB-F and PCV1-DS-ORF2-R ( Table S1 ). The infectious DNA 180 clone PCV1 backbone sequence was amplified from the PBSK+ plasmid containing 181 PCV1 in two fragments that flank the PCV1 capsid region using primers M13F (-20) and 182 PCV-BB-R, and primers PCV-DS-ORF2-F and M13R, for PCV1 fragments 1 and 2, 183 respectively ( Table S1 ). All three PCR reactions were performed using Platinum® PCR 184 Supermix (Thermo Scientific) at 94°C 3 min, 35 cycles of 94°C for 30s, 55°C for 30s, 185 and 68°C for 1 min. Fusion PCR was performed first with the PCV1 fragment 1 and the 186 shuffled PCV2 capsid 3cl14 fragment using the external primers M13F and PCV1-DS-187 ORF2-R (Table S1 ). A second fusion PCR reaction was performed with the product of 188 the first fusion PCR reaction and PCV1 fragment 2, using the external primers M13F and 189 cross-breed conventional pigs were purchased from a commercial farm that is known to 209 be free of PRRSV and M. hyo without active PCV2 circulation as determined by 210 regular PCV2 PCR on selected batches of pigs. Sows have low amounts of antibodies 211 against PCV2 or are seronegative and we selected litters from negative sows without 212 cross-fostering. The piglets were randomly assigned to six groups of 3 pigs each, and 213 each group of pigs was housed separately. Prior to inoculation, each pig was weighed, 214 bled, and confirmed to be negative for PCV2 by PCR and serology. Five groups were 215 inoculated intramuscularly each with 5 ml (10 3.66 TCID 50 /mL) of either chimeric virus 216 PCV1-2a or one of the four PCV2 capsid-shuffled viruses (PCV2-3cl13, PCV2-3cl14, 217 PCV2-3cl4-2, or PCV2-3cl12-2). One group was mock-inoculated similarly with 5 mL of 218 PBS buffer (Table 1) . Blood was collected weekly, and animals were monitored for 219 seroconversion to PCV2 capsid antibodies by ELISA and evidence of PCV2 infection by 220 qPCR. Animals were necropsied at 56 days post-infection (dpi). The weekly serum 221 samples were used to perform serum virus neutralization test against strains representing 222 different PCV2 subtypes (data not shown for 0-49 dpi). The animal study was approved 223
M13R
by Virginia Tech IACUC. and PCV2d-2 strains by IFA. Briefly, the serum samples were serially diluted 1:2 in PBS 228 and mixed with 150 TCID 50 of PCV2a, PCV2b, PCV2d-1, or PCV2d-2 virus stocks, 229 respectively, at an equal volume ratio and incubated for 1 hr at 37˚C. The serum-virus 230 mixture was then added to PK-15 cells in a 96 well plate in duplicate. After 72 hrs 231 incubation at 37˚C, an IFA was preformed using pig sera against PCV2a diluted 1:1000, 232 as the primary antibody and FITC-conjugated goat anti-pig IgG (KPL) diluted 1:50 as the 233 secondary antibody. The 50% serum neutralizing antibody titers were determined as the 234 highest dilution at which there was 50% or greater reduction in virus titer compared with 235 the average of the serum from PBS control pig group at that dilution. 236
237
Vaccination efficacy and challenge study in conventional pigs: The virus containing 238 shuffled capsid 3cl14 in the backbone of PCV2a induced significantly higher neutralizing 239 antibody responses against different PCV2 strains. Therefore, the shuffled capsid 240 sequence 3cl14 was subsequently cloned into the infectious DNA clone backbone of non-241 pathogenic PCV1 to produce a PCV1-3cl14 shuffled capsid chimeric virus as the vaccine 242
candidate. Subsequently, a pig challenge study was conducted to evaluate the efficacy of 243 the candidate PCV1-3cl14 chimeric virus vaccine against infection with currently 244 predominant circulating PCV2b as well as the emerging PCV2d-2. This experiment was 245 a subset of a larger study. However, wild type exposure prevented completion and 246 analysis of other groups .1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 Briefly, a total of 32, 3-week-old, cross-breed conventional pigs were purchased 248 from a commercial farm that is known to be free of PRRSV and M. hyopneumoniae, and 249 is negative for PCV2. The animal study was approved by Iowa State University IACUC 250 as well as by Virginia Tech IACUC. The piglets were randomly assigned to 4 groups of 251 8 pigs each. Prior to inoculation, each pig was weighed, bled, and confirmed to be 252 negative for PCV2. Groups 1 and 2 pigs were each vaccinated intramuscularly (IM) in 253 the neck region with 5 ml of the candidate PCV1-3cl14 chimeric virus vaccine (10 3.7
254
TCID 50 /mL per pig). Groups 3 and 4 pigs were each mock-vaccinated IM with 5 ml PBS 255 buffer ( Table 2 ). All animals were monitored daily for clinical signs including wasting, 256 respiratory distress, and behavioral changes such as lethargy and inappetence. Blood 257 samples were collected prior to inoculation, and weekly thereafter from each pig through 258
days post-vaccination (dpv). 259
At 42 dpv, groups 1 (vaccinated) and 3 (mock-vaccinated) pigs were each 260 challenged with 10 4.8 TCID 50 (2.5 ml intranasally and 2.5ml IM) of the PCV2b NC16845 261 virus strain, and groups 2 (vaccinated) and 4 (unvaccinated) were each similarly 262 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 (ranging from 0 to 100% of the lung affected) and lymph node size (ranging from 0 271
[normal] to 3 [four times the normal size]) were obtained for each pig (40, 41) . Sections 272 of lung, lymph nodes (superficial inguinal, mediastinal, tracheobronchial, and 273 mesenteric), tonsil, heart, thymus, kidney, spleen, and liver were collected during 274 necropsy and processed routinely for histological examination and PCV2 275 immunohistochemistry (IHC) (Iowa State University Veterinary Diagnostic Lab). Also, 276 samples of tracheobronchial lymph node (TBLN) were collected from each pig for DNA 277 extraction and quantification of PCV2 viral genomes by real-time quantitative PCR. 278
Microscopic lesions in the lymphoid tissues, lungs, heart, liver, kidney, ileum, and colon 279 were scored in a treatment status blinded manner, as described previously (40). 280 Specifically, lymph nodes, spleen, and tonsil were evaluated for presence and degree of 281 lymphoid depletion and histiocytic replacement. 282
283
Quantitative PCR to quantify viral DNA loads in serum and tissues 284
For both animal experiments we used a previously published protocol to extract DNA 285 from serum and lymph node samples and a previously published qPCR SYBR green 286 assay to quantify viral loads in these samples (37, 42) . For the pilot infection study 287 (Table 1 ) and for the challenge experiment (Table 2), PCV2 specific primers were used 288 to amplify a conserved region spanning the origin of replication and a portion of the 289 replicase gene, as previously reported (37), using primers PCV2-83F and PCV2-83R 290 (Table S1 ). For the detection of the PCV1-3cl.14 vaccine strain in the challenge study 291 (Table 2) , primers PCV1-qRepF and PCV1-qRepR primers (Table S1 ) were used to 292 amplify only the PCV1 backbone based vaccine virus DNA .1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 294 Serology: A PCV2-specific ELISA using PCV2a capsid antigen (Iowa State University 295 Veterinary Diagnostic Lab) was used to detect anti-PCV2 ORF2 IgG in each serum 296 sample as previously described (43). 297 298 Sequence confirmation of virus recovered from infected pigs: DNA extracts from 299 serum samples collected at 20 dpc from selected pigs in each group were tested by PCR 300 for PCV2 capsid sequences, and the amplified PCR products were sequenced to verify 301 that the virus recovered from the infected pigs was the same virus inoculated into the 302 animals. PCR primers Unirep-F and 2aORF-2 were used to amplify the PCV2 capsid 303 gene in these samples using the same PCR program as described above for cloning 304 (Table S1 ). Additionally, DNA extracts of TBLN tissues from selected pigs in each 305 group were also tested to confirm that the virus detected by PCR from infected pigs was 306 the same virus that was inoculated into the animals. PCV2b was amplified and 307 sequenced using primers specific for PCV2b as previously described (37). The PCV2d-2 308 vDNA was amplified and sequenced using the same forward primer as for PCV2b and a 309 PCV2d-specific reverse primer NB-56-m2b (Table S1) . 310 311 Statistical Analysis: Statistical analysis was performed using Prism v6.0 (Graphpad, La 312
Jolla CA). A one-tailed t-test was used to analyze statistical significance between two 313
groups, while a one-way ANOVA and then t-tests corrected for multiple comparisons 314 were used to determine significance between three or more groups. 315 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 65
Results
317
Generation of infectious chimeric viruses containing the shuffled capsid from 5 318 genetically distinct PCV2 strains: Traditional DNA shuffling was used to molecularly 319 breed the capsid genes from five genetically distinct PCV2 strains representing different 320 subtypes PCV2a PCV2b, PCV2c, and PCV2d-1, as well as "divergent PCV2aPCV2e" 321 (divergent PCV2a) (Fig. 1) . Although the general consensus is that previously classified 322 "divergent PCV2aPCV2e" virus isolates do not diverge enough from identified PCV2a 323 strains to be considered their own subtype (35), a "divergent PCV2aPCV2e" capsid 324 sequence was chosen to help increase the genetic diversity of the resulting shuffled 325 capsid. The capsid gene sequences from these 5 strains were shuffled using DNase I 326 digestion and reassembled by PCR without primers. A PCR product of the expected size 327 was then generated after a second round of PCR with specific primers spanning the 328 capsid gene. The shuffled capsid gene library was then cloned into the infectious clone 329 backbone of PCV2a (strain 40985) to screen for viable viruses. Of the more than 50 330 clones with "well-shuffled" capsids (containing regions from all 5 parental PCV2 331 strains), only 4 of them successfully rescued infectious virus when transfected into PK-15 332
cells (data not shown). 333
The four viruses with shuffled capsids contain a range of combinations of the 334 genetic signatures of PCV2 genomes from all 5 parental strains (Fig. 1) . The majority of 335 the unique amino acid signatures introduced into the shuffled capsids originated from 336 PCV2c, which is not surprising since PCV2c is the most genetically distinct of the 5 337 parental strains, based on a phylogenetic analysis (Fig. 2) . Therefore, we demonstrated1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 here that traditional DNA shuffling successfully generated viable infectious chimeric 339 viruses with shuffled capsid genes from 5 different PCV2 subtypes. 340 341 PCV2-3cl14 with shuffled capsid genes induces cross-neutralizing antibodies against 342 different PCV2 subtypes: To determine the viability and screen for the best virus with 343 shuffled capsids for subsequent challenge and efficacy study, we experimentally infected 344 conventional pigs with each of the four viruses (PCV2-3cl13, PCV2-3cl14, PCV2-345 3cl4_2, and PCV2-3cl12) as well as with the chimeric PCV1-2a virus (12). Serum 346 samples were collected prior to infection and weekly thereafter, and all animals were 347 monitored for serconversion to PCV2a capsid by an ELISA ( Table 1 ). All animals 348 experimentally inoculated with PCV1-2a or with PCV2-3cl14 seroconverted to PCV2 349 antibodies by 49 days post-inoculation (dpi), however only 2 out of 3 animals in the 350 PCV2-3cl12_2 and 1 of 3 pigs inoculated with either virus PCV2-3cl4 or PCV2-3cl4_2 351 were seropositive at 49 dpi ( Table 1) . 352
Serum samples collected from 56 dpi were tested by a serum virus neutralization 353 assay in PK15 cells for cross-neutralizing antibodies against wild-type PCV2a, PCV2b, a 354
PCV2d-1, and PCV2d-2 virus strains (Fig. 3) . The neutralization assay was not 355 performed against the parental PCV2c and divergent PCV2aPCV2e strains because 356
PCV2c viruses have not associated with PCV2-induced disease and attempts to grow the 357 divergent PCV2aPCV2e wild type virus in PK-15 cells was unsuccessful in our hands 358 (data not shown). Infections of pigs with 3 PCV2 viruses with shuffled capsid genes 359 (PCV2-3cl13, PCV2-3cl4_2, and PCV2-3cl12) did not induce higher levels of 360 neutralizing antibody when compared to the chimeric PCV1-2a virus which is the basis1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 for the current Fostera TM PCV commercial vaccine. However, infection of pigs with the 362 chimeric virus PCV2-3cl14 with shuffled capsid genes from different PCV2 subtypes 363 induced significantly higher neutralizing antibody titers against PCV2a and PCV2d-2 364 when compared to PCV1-2a (p<0.05) (Fig. 3) . In addition, although not statistically 365 significant, the chimeric virus PCV2-3cl14 also induced higher levels of neutralizing 366 antibody than the PCV1-2a against both PCV2b and PCV2d-2. Taken together, this pilot 367 animal study suggests that the viruses with shuffled capsid genes are viable and 368 infectious in pigs, and that one shuffled capsid virus PCV2-3cl14 induces significantly 369 higher levels of neutralizing antibodies against genetically distinct PCV2 strains when 370 compared to the other chimeric viruses as well as to the PCV1-2a vaccine virus. 371 Therefore, the virus PCV2-3cl14 was selected for the subsequent challenge and efficacy 372 study in pigs to evaluate its potential use as a novel vaccine. 373
374
The chimeric virus PCV1-3cl14 induces protective immunity in conventional pigs 375 against challenge with PCV2b and PCV2d-2. PCV2a is the genomic backbone for the 376 virus PCV2-3cl14. Therefore, in order to produce a novel vaccine candidate, we 377 subsequently transferred the shuffled capsid gene from the virus PCV2-3cl14, identified 378 in the initial cross-neutralization study, to the genomic backbone of the non-pathogenic 379 PCV1 to produce a new chimeric virus PCV1-3cl14 with a shuffled capsid. To assess 380 whether the chimeric virus PCV1-3cl14 vaccine candidate protects against challenge with 381 different PCV2 subtypes, two groups of pigs (n=8) were each vaccinated with the PCV1-382 3cl14 chimeric virus, and another two groups of pigs (n=8) were mock-vaccinated with1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 monitored for seroconversion to PCV2 capsid antibody. At 42 days post-vaccination, one 385 group of vaccinated and one group of mock-vaccinated animals were challenged with the 386 predominant field strain PCV2b currently circulating in swine herds worldwide. 387
Similarly, one vaccinated group and one mock-vaccinated group of pigs were challenged 388 with the emerging PCV2d-2 virus. Blood samples were taken weekly after challenge and 389 all animals were necropsied at 20 dpc. 390
As expected, pigs in the two vaccinated groups started to seroconvert to PCV2 391 capsid antibody by 42 dpv, whereas mock-vaccinated groups did not seroconvert until 7-392 14 dpc with PCV2b or PCV2d-2 (or 49 or 56 dpv, Table 2 , Fig. 4) . A qPCR assay 393 targeting the PCV1 replicase gene (ORF1) was used to test for PCV1-3cl14 viral DNA 394 from weekly sera, but PCV1-3cl14 viral DNA was undetectable and below the detection 395 limit of the assay in any group after vaccination (data not shown). This is consistent with 396 previous reports of the attenuated chimeric PCV1-2 virus infections in pigs (12, 37) . 397
Only 2 out of 8 animals vaccinated and subsequently challenged with PCV2b had 398 detectable viremia, and only at 14 dpc, compared to 4 and 7 out of 8 PCV2b challenge 399 control animals at 14 and 20 dpc, respectively ( Table 2) . This difference was statistically 400 significant, as the vaccinated and PCV2b challenged group had significantly lower levels 401 of viral DNA loads in sera at 20 dpc, compared to mock-vaccinated and PCV2b 402 challenged animals (p<0.01) (Fig. 5) . For animals vaccinated and subsequently 403 challenged with PCV2d-2, 1/8 at 14 dpc and 2/8 at 20 dpc had detectable viremia, while 404 7/8 PCV2d-2 challenged control animals were positive for serum viral DNA at 14 dpc 405 and 20 dpc ( Table 2) . Also, the vaccinated and PCV2d-2 challenged group had serum 406 viral DNA loads that were significantly reduced at 14 and 20 dpc (p<0.001, p<0.05 ,1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 respectively), as compared to PCV2d-2 challenge only controls (Fig. 5) . All vaccinated 408 and subsequently challenged groups had significantly lower levels of PCV2 viremia at 409 the peak of virus replication compared to control groups. In addition, all vaccinated and 410 subsequently challenged groups had significantly lower levels of detectable PCV2 DNA 411 in lymph nodes compared to mock-vaccinated and challenged groups (PCV2b = p<0.001, 412
PCV2d-2 = p<0.0001, Fig. 6 ). These results indicated that vaccination with PCV1-3cl14 413 chimeric virus significantly reduces the level of virus replication in pigs when challenged 414 with the predominant PCV2b subtype or with an emerging PCV2d-2 strain. 415
In addition to reducing viral DNA loads in sera and lymphoid tissues, vaccinated 416 animals also had a decreased PCVAD lesion score compared to unvaccinated animals 417 (Fig. 7) . Vaccinated pigs that were subsequently challenged with PCV2b had 418 significantly reduced pathological lesion scores for all measures of PCVAD, which 419 includes lymphoid depletion and histiocytic replacement in lymph nodes, spleen, and 420 tonsil tissues, as compared to unvaccinated but PCV2b challenged controls (Fig. 7) . 421
Similarly, pigs vaccinated and subsequently challenged with PCV2d-2 had significantly 422 lower pathological lesion scores for lymph node measures, as well as tonsil lymphoid 423 depletion (Fig. 8A, 8B, 8E ) as compared to unvaccinated but PCV2d-2 challenged 424 controls. Consistent with the results for serum and lymph node viral DNA detection, both 425 vaccinated and subsequently challenged groups had significantly lower viral antigen 426 scores in lymph node, spleen, and tonsil, compared to challenge only controls (Fig. 8) . 427
Overall, these results suggest that vaccination with PCV1-3cl14 chimeric virus vaccine 428 candidate protects against two genetically distinct and relevant PCV2 strains, the 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 PCV2b) subtype (18, 19, 24) , as well as the replacement of PCV2a with PCV2b as the 447 predominant circulating subtype, cannot be ignored. (18, 19, 24) . Therefore, it is logical 448 to develop the next generation of vaccines especially against the emerging PCV2 strains. 449
The objectives of this study were to molecularly breed the capsid genes from 450 different PCV2 subtypes by DNA shuffling, and to develop a candidate chimeric virus 451 vaccine based on the non-pathogenic PCV1 backbone and shuffled capsid genes of1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 divergent PCV2 subtypes. Traditional DNA shuffling approach was undertaken in this 453 study, in which 5 genetically distinct capsid sequences from each of the 4 known PCV2 454 subtypes, as well as from the "divergent PCV2aPCV2e" type (47), which is now 455 generally considered as a divergent PCV2a strain (35), were used for the DNA shuffling. 456
Of the more than 50 shuffled PCV2 capsids that were cloned and sequenced, infectious 457 chimeric viruses were rescued in PK15 cells only in 4 of them, suggesting that the small 458 PCV2 genome cannot support a large number of forced random reassortment within the 459 capsid gene. 460
The four viable viruses with shuffled PCV2 capsids generated by traditional DNA 461 shuffling contained antigenic epitopes from all 5 genetically divergent PCV2 strains, 462 although most of the variability in the shuffled capsids could be found in the PCV2c 463 parental strain. This was not unexpected, as the PCV2c subtype is the most divergent 464 strain from the rest of the PCV2 subtypes identified thus far, based on a phylogenetic 465 analysis (24, 48). Alignment of the 5 selected parental strains revealed that the PCV2c 466 does, in fact, contain the most genetically distinct amino acid variations, though some of 467 these amino acids overlap with the parental PCV2d strain, including the addition of a 468 terminal lysine residue. The presence of amino acid residues unique to PCV2c and 469 PCV2d strains suggests that, although the PCV2c subtype has not associated with any 470 clinical disease, this subtype could possibly have contributed to the evolutionary 471 emergence of the current PCV2d subtype. In fact, the PCV2c subtype was recently 472 isolated from feral pigs in Brazil for first time since it was originally described in 473 Denmark in the early 90s. The feral pig populations were also infected with the other 474 three PCV2 subtypes, suggesting the possibility of recombination (23). Therefore, these 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 findings support the inclusion of PCV2c for DNA shuffling in the current study in order 476 to increase the breadth of protection of the resulting candidate vaccine against currently 477 emerging and future possible emerging PCV2 strains. 478
In order to determine the in vivo infectivity of the shuffled viruses and to screen 479 for the best chimera for subsequent challenge and efficacy study, conventional pigs were 480 experimentally inoculated in a pilot study with each of the 4 viruses with shuffled capsids 481 in the PCV2a backbone as well as with the chimeric PCV1-2a vaccine virus (12). The 482 results showed that virus PCV2-3cl.14 induced higher levels of neutralizing antibody 483 titers when compared to the chimeric PCV1-2a virus, as well as the other 3 shuffled 484 capsid viruses. The chimeric virus PCV2-3cl.14 also induced significantly higher 485 neutralizing antibody titers against PCV2a and PCV2d-2 strains. The fact that the PCV2-486 3cl1.14 shuffled capsid virus induced higher neutralizing antibody titers against PCV2a 487 compared to a homologous vaccination with the PCV1-2a chimeric vaccine strain was 488
unexpected. However others have demonstrated this phenomenon with PCV2 viruses 489
before. Although they demonstrate opposing results, there are many differences in the 490 experimental design, which could explain these discrepenciesdiscrepancies (21, 49) . In 491 addition, the PCV2-3cl14 virus strain grew to the lowest titer of 10^3.33 TCID 50 /mL 492 compared to the other PCV2-shuffled capsid strains and the PCV1-2a vaccine strain in 493 vitro on multiple occasions (data not shown), suggesting that the increase in total and 494 breadth of neutralizing antibody titers compared to the other strains tested was not simply 495 due to increased replication efficiency. Taken together, these results demonstrate that 496 more research is needed to understand the complicated nature of PCV2 capsid 497 immunogenicity. Comparison of the amino acid sequences of the shuffled capsid 3cl14 498 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 to the other three shuffled capsids as well as the PCV1-2a reveals three regions with 499 distinct amino acid residues. Two of these regions, amino acids 106-108 and 126, 500 overlap with previously-identified B-cell antigenic epitopes (50). In addition, the 501 mutation at position 126 corresponded to a location within the predicted B-cell and SLA-502 class II epitopes (51). It is also possible that mutations within regions unrecognized as 503 immunogenic may play a direct role in the protective immune response, or alter structural 504 recognition of other immunogenic capsid regions, such as the 169-180 region shown to 505 play a "decoy" role in anti-PCV2 antibody recognition (52, 53) . While the 3cl14 residues 506 at 169-180 are identical to the strain used to demonstrate the decoy nature of this region, 507 changes at other locations may result exposure of this region to antibody neutralization. 508
While the majority of PCV2c amino acid residues introduced into the 3cl14 shuffled 509 capsid residues that map to a subset of the parental strains, but not one distinct subtype 510 have been introduced. The 3cl14 sequence contains amino acids at positions 14 and 232 511 that represent the PCV2a and "divergent PCV2a" as well as an amino acid residue that is 512 shared by PCV2d, PCV2b, and PCV2, but not divergent PCV2a or PCV2c at position 21, 513 and a residue shared by the parental PCV2b and PCV2d but not PCV2c, PCV2a, or 514 "divergent PCV2a" at position 185. Interestingly, the 3cl13, 3cl4_2, and 3cl12_2 515 shuffled capsids all contain the additional lysine residue at the C-terminus of the capsid 516 found in the PCV2d parental strain. This mutation is suggested to play a role in the 517 increased pathogenicity and vaccine failure of the emerging PCV2d strains, although no 518 direct evidence of this role has been reported to date (38, 54). However, the 3cl14 519 shuffled capsid sequence does not include the additional lysine, suggesting that it is not a 520 necessary epitope for producing neutralizing antibodies against the PCV2d-2 strains, 521 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 since PCV1-3cl14 protects against PCV2d-2 infection in the challenge and efficacy 522 experiment. While it is possible that the properties of 3cl14 capsid sequence discussed 523 above are important for production of cross-protective neutralizing antibodies in pigs, 524 additional research is warranted to determine the important amino acid residues that may 525 play a critical role in conferring cross-neutralizing activities against different PCV2 526
subtypes. 527
Based on induction of significantly higher cross-neutralizing antibody titers, 528 compared to the other shuffled capsid candidates, the shuffled 3cl14 capsid sequence was 529 subsequently selected to produce a chimeric virus PCV1-3cl14 vaccine candidate. The 530 protective efficacy of the PCV1-3cl14 chimeric virus as a potential vaccine was evaluated 531 by challenging vaccinated pigs with PCV2b or PCV2d, respectively. PCV2b is the 532 predominant subtype currently infecting pigs worldwide, whereas the PCV2d is an 533 emerging subtype (24). We previously have demonstrated the attenuation of chimeric 534 PCV1-2a and PCV1-2b viruses in the genomic backbone of the non-pathogenic PCV1 in 535 vivo (12, 37, 39) . Consistent with these previous reports, there was no detectable PCV1-536 3cl14 viremia in vaccinated pigs throughout the duration of the study, and no detectable 537 clinical disease prior to challenge with either PCV2b or PCV2d (data not shown), even 538 though the vaccinated pigs are infected as evidenced by seroconversion to PCV2 capsid 539 antibody. It is also possible that the standard PCV2a capsid-based PCV2 ORF2 ELISA 540 assay is less sensitive for detection of the PCV1-shuffle capsid induced antibodies, 541 possibly leading an underrepresentation of the antibody titers in the PCV1-3cl14 542 vaccinated groups, however further research is needed to determine if this is the case. 543
Whether the serology data is indeed blunted due to the limitations of the assay, the1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 reduction in challenge virus levels shows a significant effect of vaccination with the 545 PCV1-3cl14 vaccine candidate on PCV2b and PCV2d challenge strains. 546
Vaccination with the chimeric virus PCV1-3cl14 vaccine candidate resulted in 547 significantly reduced PCV2b or PCV2d viral DNA loads at the peak of viremia as well as 548 reduced viral DNA loads in lymphoid tissues at termination of the study. Furthermore, 549 the lymphoid lesions were also significantly reduced in vaccinated groups subsequently 550 challenged with PCV2b compared to mock-vaccinated and challenged controls. Though 551 the vaccinated animals showed no statistically significant reduction in spleen lymphoid 552 depletion and spleen and tonsil hystiocytic replacement when challenged with PCV2d, 553 they did have significant reduction for the rest of the PCVAD-associated scores, as well 554
as reduced viral DNA loads in serum and lymph node tissues, indicating that the PCV1-555 3cl14 chimeric virus vaccine candidate induced protection against both PCV2b and 556
PCV2d challenge in conventional pigs. 557
558
Conclusion
559
To our knowledge, this is the first report of construction of viable chimeric PCV2 560 vaccine candidate by shuffling the capsid gene of 5 divergent PCV2 strains belonging to 561 different subtypes. Importantly, vaccination of pigs with a chimeric virus PCV1-3cl14 562 with shuffled capsid genes induced protective immunity against challenge with the 563 predominant PCV2b subtype and the emerging PCV2d subtype. Therefore, this chimeric 564 virus is a potential candidate for further development into the next generation of vaccine 565 against PCV2. 566 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 is attenuated in vivo and induces protective and cross-protective immunity1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 of positive fluorescent foci, compared to the serum samples from the mock (PBS) inoculated control group in the same dilution. Asterisk (*) sign indicates p<0.05 analyzed using one-way ANOVA. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 DNA loads in lymph nodes using qPCR in (A) PCV2b challenged (B) and PCV2d-2 challenged animals. Group means ± SEM are plotted for each time point post-challenge.
The limit of detection for the assay was 10 7.1 copies/mg tissue of ORF1 viral DNA, as determined by a standard curve for 10 1 -10 10 copies of the wild-type PCV2b genome.
(*) Indicates statistical significance between groups at that time point (Student's t-test, corrected for multiple tests). Asterisk (*) sign indicates statistically significant differences between groups (student's t-test). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 are displayed. Asterisk (*) sign indicates statistically significant differences between groups (student's t-test).
Figure 1 a PCV2 antibody was measured at different days post-inoculation (DPI) with an ELISA using the recombinant PCV2 capsid protein as the antigen. Animals were considered to have seroconverted when samples from two or more consecutive time points were seropositive. Seropositive time points are shown in grey. 
